Not surprisingly, silencing TGF-β1 is also associated with decreased levels of Tregs and enhanced activation of effector T cells in the TME, which has a synergistic effect with VEGFA depletion using siRNA in cancer immunotherapies [80]. The gene discussed is TGFB1; the disease is cancer.